심혈관 의약품 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)
Cardiovascular Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
상품코드:1421001
리서치사:Transparency Market Research
발행일:2023년 12월
페이지 정보:영문 241 Pages
라이선스 & 가격 (부가세 별도)
한글목차
심혈관 의약품 시장 - 보고서의 범위
TMR의 세계 심혈관 의약품 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻을 수 있는 기회를 조사했습니다. 이 보고서는 세계 심혈관 의약품의 수익을 제공합니다. 2023년을 기준 연도, 2031년을 예측 연도로 간주하여 2017년부터 2031년까지 시장을 분석합니다. 이 보고서는 또한 2023년부터 2031년까지 세계 심혈관 의약품 시장의 복합 연간 성장률(CAGR%)을 제공합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하는 1차 조사에서 분석가들이 주요 오피니언 리더, 업계 리더 및 오피니언 제조업체를 인터뷰하여 파킨슨병 치료제 시장을 이해하는 데 도움을 주었으며, 2차 조사에는 주요 기업의 제품 문헌, 연례 보고서, 관련 보도자료 및 관련 문헌 참조가 포함됩니다. 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서 참조를 통해 파킨슨병 치료제 시장을 이해합니다.
시장 현황
2023년 시장 가치
1,428억 달러
2031년 시장 가치
1,956억 달러
CAGR
3.8%
이 보고서는 세계 심혈관 의약품 시장의 경쟁 환경을 자세히 조사했습니다. 세계 심혈관 의약품 시장에서 활동하는 주요 기업이 식별되고 각 기업은 다양한 속성 측면에서 프로파일링됩니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 심혈관 의약품 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
개요
시장 역학
세계 시장 분석과 예측, 2017년-2031년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 합병과 인수
COVID-19 감염증 팬데믹이 업계에 미치는 영향
제6장 세계 시장 분석과 예측 : 약제 클래스별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 약제 클래스별, 2017년-2031년
레닌안지오텐신계 차단약
ACE 억제제
안지오텐신 수용체 차단약
베타 차단제
이뇨제
항응고제
항응고제
혈소판 응집 억제제
고지혈증 치료제
기타 강압제
칼슘 채널 차단제
기타
시장 매력 분석 : 약제 클래스별
제7장 세계 시장 분석과 예측 : 적응증별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 지표별, 2017년-2031년
고혈압
고지혈증
관상동맥 질환
말초동맥 질환
부정맥
기타
시장의 매력 분석 : 적응증별
제8장 세계 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 유통 채널별, 2017년-2031년
병원 약국
소매 약국
온라인 약국
시장의 매력 분석 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2017년-2031년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 분석 : 지역별
제10장 북미 시장 분석과 예측
제11장 유럽 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 라틴아메리카 시장 분석과 예측
시장 매출 예측 : 유통 채널별, 2017년-2031년
병원 약국
소매 약국
온라인 약국
시장 매출 예측 : 국/서브 지역별, 2017년-2031년
브라질
멕시코
기타 라틴아메리카
시장의 매력 분석
약제 클래스별
적응증별
유통 채널별
국가/하위 지역별
제14장 중동 및 아프리카 시장 분석과 예측
제15장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
AstraZeneca
Pfizer Inc.
Novartis AG
Merck &Co. Inc.
Bristol-Myers Squibb Company
Bayer AG
Sanofi
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Gilead Sciences, Inc.
Johnson &Johnson
Astellas Pharma, Inc.
Eli Lilly and Company
Otsuka Holdings Co., Ltd.
Takeda Pharmaceuticals Company Ltd.
LSH
영문 목차
영문목차
Cardiovascular Drugs Market - Scope of Report
TMR's report on the global Parkinson's disease therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Parkinson's disease therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Parkinson's disease therapeutics market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Parkinson's disease therapeutics market.
Market Snapshot
Market Value in 2023
US$ 142.8 Bn
Market Value in 2031
US$ 195.6 Bn
CAGR
3.8%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Parkinson's disease therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Parkinson's disease therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Parkinson's disease therapeutics market.
The report delves into the competitive landscape of the global Parkinson's disease therapeutics market. Key players operating in the global Parkinson's disease therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Parkinson's disease therapeutics market profiled in this report.
Key Questions Answered in Global Parkinson's disease therapeutics Market Report:
What is the sales/revenue generated by Parkinson's disease therapeutics across all regions during the forecast period?
What are the opportunities in the global Parkinson's disease therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Cardiovascular Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global Parkinson's disease therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Parkinson's disease therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Parkinson's disease therapeutics market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiovascular Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiovascular Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Cardiovascular Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Renin-Angiotensin System Blockers
6.3.1.1. ACE Inhibitors
6.3.1.2. Angiotensin Receptor Blockers
6.3.2. Beta Blockers
6.3.3. Diuretics
6.3.4. Anti-Clotting Agents
6.3.4.1. Anti-Coagulants
6.3.4.2. Platelet Aggregation Inhibitors
6.3.5. Antihyperlipidemics
6.3.6. Other Antihypertensive
6.3.7. Calcium Channel Blockers
6.3.8. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Cardiovascular Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Hypertension
7.3.2. Hyperlipidemia
7.3.3. Coronary Artery Disease
7.3.4. Peripheral Artery Disease
7.3.5. Arrhythmia
7.3.6. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Cardiovascular Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Cardiovascular Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cardiovascular Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017-2031
10.3.1. Renin-Angiotensin System Blockers
10.3.1.1. ACE Inhibitors
10.3.1.2. Angiotensin Receptor Blockers
10.3.2. Beta Blockers
10.3.3. Diuretics
10.3.4. Anti-Clotting Agents
10.3.4.1. Anti-Coagulants
10.3.4.2. Platelet Aggregation Inhibitors
10.3.5. Antihyperlipidemics
10.3.6. Other Antihypertensive
10.3.7. Calcium Channel Blockers
10.3.8. Others
10.4. Market Value Forecast, by Indication, 2017-2031
10.4.1. Hypertension
10.4.2. Hyperlipidemia
10.4.3. Coronary Artery Disease
10.4.4. Peripheral Artery Disease
10.4.5. Arrhythmia
10.4.6. Others
10.5. Market Value Forecast, by Distribution Channel, 2017-2031
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Cardiovascular Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017-2031
11.3.1. Renin-Angiotensin System Blockers
11.3.1.1. ACE Inhibitors
11.3.1.2. Angiotensin Receptor Blockers
11.3.2. Beta Blockers
11.3.3. Diuretics
11.3.4. Anti-Clotting Agents
11.3.4.1. Anti-Coagulants
11.3.4.2. Platelet Aggregation Inhibitors
11.3.5. Antihyperlipidemics
11.3.6. Other Antihypertensive
11.3.7. Calcium Channel Blockers
11.3.8. Others
11.4. Market Value Forecast, by Indication, 2017-2031
11.4.1. Hypertension
11.4.2. Hyperlipidemia
11.4.3. Coronary Artery Disease
11.4.4. Peripheral Artery Disease
11.4.5. Arrhythmia
11.4.6. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Cardiovascular Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017-2031
12.3.1. Renin-Angiotensin System Blockers
12.3.1.1. ACE Inhibitors
12.3.1.2. Angiotensin Receptor Blockers
12.3.2. Beta Blockers
12.3.3. Diuretics
12.3.4. Anti-Clotting Agents
12.3.4.1. Anti-Coagulants
12.3.4.2. Platelet Aggregation Inhibitors
12.3.5. Antihyperlipidemics
12.3.6. Other Antihypertensive
12.3.7. Calcium Channel Blockers
12.3.8. Others
12.4. Market Value Forecast, by Indication, 2017-2031
12.4.1. Hypertension
12.4.2. Hyperlipidemia
12.4.3. Coronary Artery Disease
12.4.4. Peripheral Artery Disease
12.4.5. Arrhythmia
12.4.6. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacy
12.5.2. Retail Pharmacy
12.5.3. Online Pharmacy
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Cardiovascular Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017-2031
13.3.1. Renin-Angiotensin System Blockers
13.3.1.1. ACE Inhibitors
13.3.1.2. Angiotensin Receptor Blockers
13.3.2. Beta Blockers
13.3.3. Diuretics
13.3.4. Anti-Clotting Agents
13.3.4.1. Anti-Coagulants
13.3.4.2. Platelet Aggregation Inhibitors
13.3.5. Antihyperlipidemics
13.3.6. Other Antihypertensive
13.3.7. Calcium Channel Blockers
13.3.8. Others
13.4. Market Value Forecast, by Indication, 2017-2031
13.4.1.1. Hypertension
13.4.1.2. Hyperlipidemia
13.4.1.3. Coronary Artery Disease
13.4.1.4. Peripheral Artery Disease
13.4.1.5. Arrhythmia
13.4.1.6. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacy
13.5.2. Retail Pharmacy
13.5.3. Online Pharmacy
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Cardiovascular Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017-2031
14.3.1. Renin-Angiotensin System Blockers
14.3.1.1. ACE Inhibitors
14.3.1.2. Angiotensin Receptor Blockers
14.3.2. Beta Blockers
14.3.3. Diuretics
14.3.4. Anti-Clotting Agents
14.3.4.1. Anti-Coagulants
14.3.4.2. Platelet Aggregation Inhibitors
14.3.5. Antihyperlipidemics
14.3.6. Other Antihypertensive
14.3.7. Calcium Channel Blockers
14.3.8. Others
14.4. Market Value Forecast, by Indication, 2017-2031
14.4.1. Hypertension
14.4.2. Hyperlipidemia
14.4.3. Coronary Artery Disease
14.4.4. Peripheral Artery Disease
14.4.5. Arrhythmia
14.4.6. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacy
14.5.2. Retail Pharmacy
14.5.3. Online Pharmacy
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Indication
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
